Hologic Diagenode's longstanding expertise in epigenomics, when coupled with cutting-edge AI and machine learning approaches, leads to biomarker signature identification. DNA methylation signatures are highly sensitive and specific, making them ideal for early detection, surveillance screening, and monitoring of minimal residual disease (MRD) for cancer and beyond.
Tissue-specific and cancer-specific DNA methylation profiles can be found in previously published and publicly available databases or via genome-wide de novo analysis, such as our WGBS/EM-seq, Human Methylome, EPIC array and Methylation Screening Array.
Biomarker signatures can be identified bioinformatically using AI and Machine Learning (ML) analysis approaches.
Biomarkers could then be validated on an independent cohort, publicly available or via new data generated from our custom Targeted Methyl-seq.
Damien Calay
Bioinformatic Scientist
Hologic Diagenode
